Cyril Lervat

1.7k total citations
33 papers, 191 citations indexed

About

Cyril Lervat is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Cyril Lervat has authored 33 papers receiving a total of 191 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Cyril Lervat's work include Sarcoma Diagnosis and Treatment (10 papers), Childhood Cancer Survivors' Quality of Life (8 papers) and Renal and related cancers (5 papers). Cyril Lervat is often cited by papers focused on Sarcoma Diagnosis and Treatment (10 papers), Childhood Cancer Survivors' Quality of Life (8 papers) and Renal and related cancers (5 papers). Cyril Lervat collaborates with scholars based in France, United States and Canada. Cyril Lervat's co-authors include Perrine Marec‐Bérard, Laurence Brugières, Nathalie Gaspar, Anne Sophie Defachelles, Yves Gillet, D. Floret, Nicolas Penel, Pierre Cochat, Jean‐Claude Gentet and Bruno Ranchin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Cyril Lervat

26 papers receiving 188 citations

Peers

Countries citing papers authored by Cyril Lervat

Since Specialization

Citations

This map shows the geographic impact of Cyril Lervat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyril Lervat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyril Lervat more than expected).

Fields of papers citing papers by Cyril Lervat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyril Lervat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyril Lervat. The network helps show where Cyril Lervat may publish in the future.

Co-authorship network of co-authors of Cyril Lervat

This figure shows the co-authorship network connecting the top 25 collaborators of Cyril Lervat. A scholar is included among the top collaborators of Cyril Lervat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyril Lervat. Cyril Lervat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Radiothérapie des sarcomes d’Ewing 2025 ·Bulletin du Cancer ·L. Claude, Sylvie Helfré, Nadège Corradini, Nathalie Gaspar, Pablo Berlanga, Laure Saumet, Perrine Marec‐Bérard, Cyril Lervat, M. Ropars, Sophie Piperno‐Neumann, (unknown), (unknown), Anne Ducassou, (unknown)	0
2	A Review of GO-AJA’s Impact on Adolescents and Young Adults with Cancer in France: A Decade of Progress and Challenges 2024 ·Journal of Adolescent and Young Adult Oncology ·Marilyne Poirée, (unknown), (unknown), Pierre Leblond, Valérie Laurence, Nathalie Gaspar, (unknown), Cyril Lervat, Perrine Marec‐Bérard	1
3	1755P Multimodal therapy in first line treatment of very high risk Ewing sarcoma patients: Results of the French prospective multicenter COMBINAIR3 phase II trial 2024 ·Annals of Oncology ·Valérie Laurence, (unknown), Sylvain Dureau, Nina Jehanno, Gaëlle Pierron, (unknown), (unknown), (unknown), Cyril Lervat, Sophie Taque, (unknown), (unknown), (unknown), (unknown), Laure Saumet, Cécile Verite, (unknown), Estelle Thébaud, Mehdi Brahmi, (unknown)	1
4	A Qualitative Study on the Transition from Pediatric to Adult Care in Oncology: How Health Care Professionals Can Adapt Their Practice? 2024 ·Journal of Adolescent and Young Adult Oncology ·(unknown), (unknown), Cécile Flahault, Cyril Lervat, Pascal Antoine, (unknown), Kristopher Lamore	0
5	Consensus survey on the management of children with chemotherapy-induced febrile neutropenia and at low risk of severe infection 2023 ·Pediatric Hematology and Oncology ·(unknown), (unknown), (unknown), (unknown), Cyril Lervat, François Dubos	0
6	Soins de support en oncologie pédiatrique ou le respect des besoins fondamentaux des enfants et adolescents 2022 ·Bulletin du Cancer ·Marilyne Poirée, (unknown), (unknown), Sandrine Thouvenin, (unknown), F. Galland, (unknown), Cyril Lervat	0
7	Nausées-vomissements induits par les traitements anticancéreux (NVITAC) en onco-hématologie pédiatrique : recommandations 2022 du Comité soins de support de la SFCE 2022 ·Bulletin du Cancer ·(unknown), (unknown), A. Bertrand, (unknown), (unknown), Dominique Lévy, (unknown), Cyril Lervat, Marilyne Poirée	0
8	Les soins de support pour améliorer l’accompagnement personnalisé des patients 2020 ·Bulletin du Cancer ·Cyril Lervat, Laurence Vanlemmens, P. Bondil, (unknown), Florian Scotté, (unknown)	3
9	A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma 2019 ·European Journal of Cancer ·Perrine Marec‐Bérard, Cécile Dalban, Nathalie Gaspar, Laurence Brugières, Jean‐Claude Gentet, Cyril Lervat, Nadège Corradini, Marie‐Pierre Castex, Claudine Schmitt, Hélène Pacquement, Marie‐Dominique Tabone, Mehdi Brahmi, (unknown), Jean‐Yves Blay, David Pérol	21
10	Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years 2019 ·Journal of Adolescent and Young Adult Oncology ·Perrine Marec‐Bérard, Valérie Laurence, Bob‐Valéry Occéan, Isabelle Ray‐Coquard, Claude Linassier, Nadège Corradini, Olivier Collard, L. Chaigneau, Didier Cupissol, Pierre Kerbrat, Esma Saâda-Bouzid, Corinne Delcambre, F. Gouin, Cécile Guillemet, Marta Jimenez, Cyril Lervat, Nathalie Gaspar, Marie‐Cécile Le Deley, Laurence Brugières, Sophie Piperno‐Neumann	12
11	Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study 2019 ·BMJ Supportive & Palliative Care ·(unknown), A. Bertrand, Léa Guerrini‐Rousseau, Anne Pagnier, (unknown), Cyril Lervat, (unknown), (unknown), (unknown), Sandrine Thouvenin, Christophe Piguet, Claudine Schmitt, Perrine Marec‐Bérard	16
12	Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study 2017 ·BMC Cancer ·Marie‐Dominique Tabone, Laurence Brugières, Sophie Piperno‐Neumann, (unknown), Perrine Marec‐Bérard, Hélène Pacquement, Cyril Lervat, Nadège Corradini, Jean‐Claude Gentet, Rémy Couderc, (unknown), (unknown), Natacha Entz‐Werlé, Jean‐Yves Blay, Marie‐Cécile Le Deley	5
13	Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome 2016 ·Bulletin du Cancer ·(unknown), (unknown), Anne Sophie Defachelles, Cyril Lervat, Thomas Ryckewaert, (unknown), (unknown), Dominique Deplanque, Nicolas Penel	9
14	Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients 2016 ·European Journal of Surgical Oncology ·(unknown), (unknown), Delphine Hudry, Sophie Cousin, Cyril Lervat, (unknown), (unknown), Sophie El Bedoui, Gauthier Decanter, (unknown), (unknown), (unknown), Nicolas Penel, Emmanuelle Tresch‐Bruneel, Fabrice Narducci	26
15	HIGH-DOSE¹³¹I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS 2016 ·Radiation Protection Dosimetry ·(unknown), Anne Sophie Defachelles, Philippe Carpentier, Cyril Lervat, Stéphanie Clisant, A. Oudoux, H. Kolesnikov-Gauthier	9
16	Intérêt d’une approche socioéducative dans l’accompagnement des adolescents et jeunes adultes atteints de cancer : l’exemple lillois 2016 ·Bulletin du Cancer ·(unknown), (unknown), Hélène Bricout, Cyril Lervat, (unknown), Pierre Leblond, Anne Sophie Defachelles, Nicolas Penel, Hélène Sudour‐Bonnange	2
17	A Sex Cord-stromal Tumor, Specifically a Fibroma, Arising From the Uterine Corpus 2015 ·International Journal of Gynecological Pathology ·Hélène Sudour‐Bonnange, N. Rocourt, E. Aubry, Cyril Lervat, Olivier Kerdraon	2
18	Dilated Cardiomyopathy Caused by Wilms Tumor 2015 ·Pediatric Emergency Care ·(unknown), (unknown), Cyril Lervat, Xavier Leroy, M. Bonnevalle, Morgan Recher, Hélène Sudour‐Bonnange	7
19	^99mTc-DTPA-bis-c(RGDfK) a potential alpha(v)beta3 integrin based homobivalent radioligand for imaging neoangiogenesis in malignant glioma and melanoma 2015 ·RSC Advances ·(unknown), Jürgen Schulz, Catherine Savona‐Baron, Puja Panwar Hazari, Cyril Lervat, (unknown), (unknown), Nicole Barthe, B. Vergier, Philippe Fernandez	4
20	High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group 2014 ·Sarcoma ·Perrine Marec‐Bérard, Céline Ségura‐Ferlay, Marie‐Dominique Tabone, Hélène Pacquement, Cyril Lervat, Jean‐Claude Gentet, Claudine Schmitt, Nathalie Gaspar, Laurence Brugières	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact